Abstract
The increasing debate regarding the predictiveness of rodent persistent pain models for clinical efficacy has spurred rapidly evolving numbers and types of novel models from which to choose. While several excellent reviews of these models have been published in recent years, few focus on their specific applications and particular challenges with the use of these models in the setting of drug discovery. Thus, in this review, how models of persistent pain may be used to: 1) screen molecules for in vivo efficacy, 2) advance lead compounds and 3) guide decision making for clinical trial design is discussed. Relative to other disease areas for potential drug discovery and development, chronic pain appears to be well-poised for drug discovery and development. This is in large part due to the advanced understanding of pain mechanisms and the upsurge in the development of novel, specialized rodent models of persistent pain and improvements in methods of pain assessment in animals.
Keywords: Animal models, behavioral assays, behavioral pharmacology, drug discovery, in vivo efficacy models, pain models, predictive validity, translational research, rodent persistent pain models, clinical efficacy, persistent pain, upsurge, nerve injury, chronic inflammation
Current Pharmaceutical Biotechnology
Title: Rodent Models of Persistent Pain in Drug Discovery and Development
Volume: 12 Issue: 10
Author(s): William A. Eckert
Affiliation:
Keywords: Animal models, behavioral assays, behavioral pharmacology, drug discovery, in vivo efficacy models, pain models, predictive validity, translational research, rodent persistent pain models, clinical efficacy, persistent pain, upsurge, nerve injury, chronic inflammation
Abstract: The increasing debate regarding the predictiveness of rodent persistent pain models for clinical efficacy has spurred rapidly evolving numbers and types of novel models from which to choose. While several excellent reviews of these models have been published in recent years, few focus on their specific applications and particular challenges with the use of these models in the setting of drug discovery. Thus, in this review, how models of persistent pain may be used to: 1) screen molecules for in vivo efficacy, 2) advance lead compounds and 3) guide decision making for clinical trial design is discussed. Relative to other disease areas for potential drug discovery and development, chronic pain appears to be well-poised for drug discovery and development. This is in large part due to the advanced understanding of pain mechanisms and the upsurge in the development of novel, specialized rodent models of persistent pain and improvements in methods of pain assessment in animals.
Export Options
About this article
Cite this article as:
A. Eckert William, Rodent Models of Persistent Pain in Drug Discovery and Development, Current Pharmaceutical Biotechnology 2011; 12 (10) . https://dx.doi.org/10.2174/138920111798357456
DOI https://dx.doi.org/10.2174/138920111798357456 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Regulation of Vascular Genes by Glucose
Current Pharmaceutical Design Type 2 Diabetes Mellitus and Invokana: An FDA Approved Drug
Current Diabetes Reviews Cyclooxygenase-2 Pathway as a Potential Therapeutic Target in Diabetic Peripheral Neuropathy
Current Drug Targets The Emerging Role of Endocrine Disruptors in Pathogenesis of Insulin Resistance: A Concept Implicating Nonalcoholic Fatty Liver Disease
Current Molecular Medicine Commentary Research Highlights (Purines, Pores and Pain: Is it in Our Genes?)
CNS & Neurological Disorders - Drug Targets Validation of TZD Scaffold as Potential ARIs: Pharmacophore Modeling, Atom-based 3D QSAR and Docking Studies
Combinatorial Chemistry & High Throughput Screening Nano-biotechnology and its Innovative Perspective in Diabetes Management
Mini-Reviews in Medicinal Chemistry Valproate and Neuroendocrine Changes in Relation to Women Treated for Epilepsy and Bipolar Disorder: A Review
Current Medicinal Chemistry Interrelationships with Metabolic Syndrome, Obesity and Cardiovascular Risk
Current Vascular Pharmacology Obesity and Arterial Compliance Alterations
Current Vascular Pharmacology Effect of Adding Proprioceptive Exercise to Balance Training in Older Adults with Diabetes: A Systematic Review
Current Diabetes Reviews Ca<sup>2+</sup> Signalling in Endothelial Progenitor Cells: A Novel Means to Improve Cell-Based Therapy and Impair Tumour Vascularisation
Current Vascular Pharmacology Diabetes and Heart Failure: Is it Hyperglycemia or Hyperinsulinemia?
Current Vascular Pharmacology Target-oriented Mechanisms of Novel Herbal Therapeutics in the Chemotherapy of Gastrointestinal Cancer and Inflammation
Current Pharmaceutical Design Phosphodiesterase Type 5 Inhibitors: Unmet Needs
Current Pharmaceutical Design Tetracyclines and Neuromuscular Disorders
Current Neuropharmacology Glycation and Hypoxia: Two Key Factors for Adipose Tissue Dysfunction
Current Medicinal Chemistry Opioid-modulating Peptides: Mechanisms of Action
Current Topics in Medicinal Chemistry Effects of Metabolic Approach in Diabetic Patients with Coronary Artery Disease
Current Pharmaceutical Design Harnessing Stem Cell Potential for the Treatment of Erectile Function in Men with Diabetes Mellitus: From Preclinical/Clinical Perspectives to Penile Tissue Engineering
Current Stem Cell Research & Therapy